scholarly journals Pure red-cell aplasia requiring cytotoxic chemotherapy: Presence of clonal T-lymphocytes without characteristics of chronic lymphocytic leukemia

1996 ◽  
Vol 53 (2) ◽  
pp. 145-147
Author(s):  
Masahiko Nezu ◽  
Eiichiro Kawano ◽  
Hideshi Ishii ◽  
Miki Nishimura ◽  
Akira Hirasawa ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
T Lymphocytes ◽  
Pure Red Cell Aplasia ◽  
Cytotoxic Chemotherapy ◽  
Lymphocytic Leukemia ◽  
Red Cell ◽  
Red Cell Aplasia

Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia

Blood ◽  
2002 ◽  
Vol 99 (3) ◽  
pp. 1092-1094 ◽  
Author(s):  
Hassan Ghazal
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
De Novo ◽  
Rare Complication ◽  
Pure Red Cell Aplasia ◽  
High Serum ◽  
Lymphocytic Leukemia ◽  
Red Cell ◽  
Coombs Test ◽  
Red Cell Aplasia ◽  
Short Period

Abstract Pure red cell aplasia (PRCA) is a rare complication in patients with chronic lymphocytic leukemia (CLL). It is characterized by reticulocytopenia and by an absence of red cell precursors in the bone marrow. Unlike autoimmune hemolytic anemia, which is characterized by an increased number of reticulocytes, positive Coombs test findings, and a high serum level of lactate dehydrogenase. Two patients with B-cell CLL are reported to have developed PRCA, one while on chemotherapy with fludarabine and one seeking treatment for de novo PRCA. Both responded dramatically to therapy with monoclonal antibody rituximab (Rituxan) in a short period of time and continued to be transfusion-independent. These are the first 2 reported patients for whom rituximab treatment for PRCA in CLL was successful, and this treatment deserves further investigation.

Sign in / Sign up

Export Citation Format

Share Document